Are there ongoing phase 2 or phase 3 randomized controlled trials testing gelatide for obesity?
Executive summary
Available reporting and trial listings show many anti‑obesity drugs advancing through phase 2 and phase 3, but none of the supplied sources mention an agent named “gelatide” or any randomized phase 2/3 trials of a product by that name (available sources do not mention gelatide). Industry overviews count hundreds of active obesity assets and new late‑stage trials in 2024–25, but the specific term “gelatide” does not appear in the provided materials [1] [2].
1. No mention of “gelatide” in the assembled reporting — a clear negative in the record
I searched the supplied set of articles and trial summaries: sources catalog industry pipelines, phase‑2 and phase‑3 programs by name (examples include AZD6234 and maridebart/maritide), but none reference a molecule or program called “gelatide.” The absence is explicit in these materials: GlobalData/industry summaries list hundreds of assets and notable late‑stage trials but do not list gelatide [1] [2]. Therefore, based on the available sources, there is no documented ongoing phase‑2 or phase‑3 randomized controlled trial for a product named gelatide (available sources do not mention gelatide).
2. The obesity pipeline is crowded — many late‑stage trials are active, so omission is notable
Industry commentary and databases describe a surge of anti‑obesity medication (AOM) programs in phases I–III, with 157 to several hundred assets reported and 2024 described as a record year for trials; 2025 continues with many planned and ongoing late‑stage studies [1] [2]. Examples in the provided snippets include AstraZeneca’s AZD6234 in a randomized phase 2b trial and Amgen’s maritide moving into Phase 3 programs, illustrating that named candidates are tracked and publicly reported [3] [4].
3. Where named phase‑2/3 trials do appear in sources
The supplied materials show concrete trial activity for other compounds: AstraZeneca’s phase 2b randomized, double‑blind, placebo‑controlled AZD6234 study in people with obesity (start 01 Oct 2024; primary completion Aug 8, 2025) is listed on AstraZeneca’s trial pages [3]. Amgen reported Phase 2 results for monthly maritide and says Phase 3 chronic weight‑management studies are actively enrolling and additional Phase 3 outcome studies are planned [4]. These examples show how the major programs are named and tracked in public reporting [3] [4].
4. Why “gelatide” might be absent — three plausible explanations from context
First, it may be an early‑stage preclinical candidate or an alternate name (research code) not yet public — many compounds never reach late‑stage trials and industry lists focus on advanced assets [1] [2]. Second, the name could be a misspelling or conflation with another product (the reporting shows many similar‑sounding investigational names, e.g., maridebart/maritide) and would thus not appear under “gelatide” [4]. Third, it may exist but outside the datasets supplied here — clinicaltrials.gov, company pipelines and industry trackers are typical places for trial registration, but those specific records were not included in the supplied set for “gelatide” (available sources do not mention gelatide).
5. What the sources do document about trial trends you should know
The obesity field is shifting: more innovators, more combination and multi‑agonist approaches, and growing numbers of phase‑2/3 programs aiming for regulatory and real‑world validation [2] [5]. Regulators and analysts are pushing for trials that better reflect clinical populations, and sponsors are moving promising candidates into larger outcome‑driven Phase‑3 programs [2] [6]. This context means that if gelatide were a bona fide late‑stage program it would likely appear in at least one of the industry summaries or trial registries cited here; it does not [1] [2].
6. How you can confirm further (next steps and caveats)
To resolve definitively, consult clinicaltrials.gov or company pipeline pages for the exact spelling and any code names; search registries and press releases for synonyms or developer names. The supplied materials are thorough on many late‑stage programs but do not substitute for a full registry search (available sources do not mention gelatide; [7] for clinicaltrials.gov reference). If you want, I can run targeted registry searches or check major developer announcements in a follow‑up, using correctly spelled names or likely code‑name variants.
Limitations: This analysis uses only the supplied sources. If gelatide appears in documents or registries outside this set, those records were not provided here and therefore not reflected in this report (available sources do not mention gelatide).